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A B S T R A C T
Background: This study was designed to compare efﬁcacy and safety among novel oral anticoagulants
(NOACs), which have not been directly compared in randomized control trials to date.
Method: We performed network meta-analyses of randomized control trials in preventing thrombo-
embolic events and major bleeding in patients with atrial ﬁbrillation. PubMed, Embase, and the
Cochrane Database of Systematic Reviews for published studies and various registries of clinical trials for
unpublished studies were searched for 2002–2013. All phase III randomized controlled trials (RCTs) of
NOACs (apixaban, edoxaban, dabigatran, rivaroxaban), idraparinux, and ximelagatran were reviewed.
Results: A systematic literature search identiﬁed nine phase III RCTs for primary analyses. The efﬁcacy of
each NOAC was similar with respect to our primary composite endpoint following adjustment for open
label designs [odds ratios (ORs) versus vitamin K antagonists: apixaban 0.79; dabigatran 150 mg 0.77;
edoxaban 60 mg 0.87; rivaroxaban 0.86] except for dabigatran 110 mg and edoxaban 30 mg. Apixaban
and edoxaban 30 mg and 60 mg had signiﬁcantly fewer major bleeding events than dabigatran 150 mg,
ricvaroxaban, and vitamin K antagonists. All NOACs were similar in reducing secondary endpoints with
the exception of dabigatran 110 mg and 150 mg which were associated with a signiﬁcantly greater
incidence of myocardial infarction compared to apixaban, edoxaban 60 mg, and rivaroxaban.
Conclusions: Our indirect comparison with adjustment for study design suggests that the efﬁcacy of the
examined NOACs is similar across drugs, but that some differences in safety and risk of myocardial
infarction exist, and that open label study designs appear to overestimate safety and treatment efﬁcacy.
Differences in study design should be taken into account in the interpretation of results from RCTs of
NOACs.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The introduction of novel oral anticoagulants (NOACs) has
ushered in a new era in treatment strategies for the prevention of
stroke and systemic embolism in patients with atrial ﬁbrillation.
However, as all approved NOACs were compared with vitamin K
antagonists in their respective phase III trials, possible differences* Corresponding author at: Department of Clinical Pharmacology & Therapeutics,
University of the Ryukyus School of Medicine, 207 Uehara, Nishihara-cho, Okinawa
903-0215, Japan. Tel.: +81 98 895 1195; fax: +81 98 895 1447.
E-mail address: blessyou@med.u-ryukyu.ac.jp (S. Ueda).
http://dx.doi.org/10.1016/j.jjcc.2015.05.018
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsin the efﬁcacy and safety among individual drugs have not yet been
formally tested. Moreover, study design has varied widely among
clinical trials of NOACs, potentially inﬂuencing individual study
results as well as confounding cross-study analyses.
An example of the former includes the Stroke Prevention Using
Oral Thrombin Inhibitor in Atrial Fibrillation Trial (SPORTIF) III [1]
and SPORTIF V [2] studies, which reported divergent results in
open design and double-blind comparisons of ximelagatran and
warfarin. This potential study design effect is further supported by
a pair of systematic reviews. Schulz et al. assessed the methodo-
logical quality of 33 meta-analyses, containing 250 controlled
trials, to evaluate study differences impacting treatment efﬁcacy
and found that trials that were not adequately blinded signiﬁcantly reserved.
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analysis to evaluate the extent of potential bias related to open
versus blinded studies and found similar results [4].
In addition to concerns of study design, patient factors may also
complicate comparisons of NOAC ﬁndings. White et al. reported
that clinical outcomes, including risk of death, stroke and systemic
embolism, myocardial infraction, and major bleeding, were
correlated to international normalized ratio (INR) control in
patients with atrial ﬁbrillation taking a vitamin K antagonist
(warfarin) [5]. Such a patient condition-mediated outcome
variability in response to vitamin K antagonist therapy could pose
a potential stumbling block for inter-study analyses.
In order to adjust for potential study design biases and outcome
variability due to patient condition and to effectively compare the
safety and efﬁcacy of NOACs and vitamin K antagonists using the
available data, we conducted an indirect comparison by network
meta-analysis of the available literature. The novelty of our
analysis is indirect comparison of NOACs based on results adjusted
for un-blindness, which might have been relevant in the
assessment of efﬁcacy and safety of NOACs compared to warfarin.
Methods
Study design
We conducted a network meta-analysis to compare NOACs in
preventing thromboembolic events in patients with atrial ﬁbrilla-
tion. In our present study, we deﬁned apixaban, betrixaban,
dabigatran, edoxaban, and rivaroxaban as NOACs; ximelagatran as
an oral anticoagulant; and warfarin, idraparinux, and aspirin as
comparators. Our literature search included all phase III random-
ized controlled trials (RCTs) of NOACs for the primary analysis. In
instances where two doses were examined in one trial, we
considered both doses as independent interventions.
Neither the approval of an institutional review board nor
informed consent was required due to the nature of our study
design.
Patients and endpoints
We included patients with either chronic or paroxysmal atrial
ﬁbrillation, irrespective of cause. No criteria were enforced for
gender or age.
The primary endpoint was a composite of stroke and systemic
embolism. Stroke was deﬁned to include ischemic, hemorrhagic,
and uncertain stroke, but not transient ischemic attack; systemic
embolism included any embolism other than cerebrovascular or of
a cardiac origin. Secondary endpoints included stroke and
myocardial infarction. We included major bleeding as a safety
endpoint. Other endpoints of interest included: all-cause death,
ischemic stroke (including stroke of unknown origin), hemorrhagic
stroke, and intracranial hemorrhage.
Literature search
One investigator (KW) conducted the literature search through
PubMed, Embase, and the Cochrane Database of Systematic Reviews
for published studies meeting inclusion criteria. We also reviewed
registries of clinical trials (TrialResults-center, clinicalstudyresult-
s.org, clinicaltrials.gov, the World Health Organization International
Clinical Trials Registry Platform), ISI Web of Knowledge, the US Food
and Drug Administration, and the European Medicines Agency sites
for unpublished studies. References from retrieved articles found
were also examined.
Our search included terms for the following interventions:
apixaban, betrixaban, dabigatran, edoxaban, rivaroxaban, andximelagatran. We included all English language studies published
between January 1, 2002 and December 31, 2013. The population
of interest was patients with atrial ﬁbrillation. Retrieved studies
were limited to phase III RCTs. Complete search strategy details are
provided in Appendix 1 as Table A1.
Data extraction and synthesis
Two investigators (TM, SU) independently assessed articles
identiﬁed by the literature search for inclusion, and articles
fulﬁlling inclusion criteria were compiled for data extraction and
synthesis.
A network meta-analysis was conducted by a statistician (BC)
taking into account study bias and correcting for indirect
comparisons. This approach was based on an empirical estimate
of bias from meta-epidemiological studies comparing results of
open studies with those of double-blind studies addressing the
same research question (treatment and disease). The mean
empirical bias (and its distribution) was obtained by calculating
the ratio of the odds ratios (ORs), that is, dividing the OR from the
open studies by the OR of the double-blind studies. A ratio of less
than 1 indicates an overestimation of effect by the open studies.
This method incorporates not only the magnitude but also the
uncertainly of the bias (its distribution). We used the method
described by Ju¨ni et al. [4] to estimate the pooled ORs for taking
study design into account. Statistical techniques for network
analyses have been described elsewhere [6]. In brief, to obtain the
OR for two treatments A versus B (ORAB), we divided the OR for A
versus C by the OR for B versus C. Conﬁdence intervals were
calculated as EXPðlnðORABÞ  1:96
p½SE2AC þ SE2BCÞ where the SE is
from the log-odds. Network analyses require the same assump-
tions as traditional meta-analyses in that studies are assumed to be
independent and should be performed under similar conditions.
Adjustments for open and blinded studies were made to account
for this difference; however, other study differences that could
impact outcomes were evaluated and are discussed in the
limitations. Microsoft Excel 2010 for Windows was used for
statistical analyses and graphical presentation.
We ﬁrst estimated the pooled ORs of the NOACs compared to
vitamin K antagonists with and without an adjustment of study
design on the primary and safety endpoints. If a study design
effect was observed, we thereafter used the bias adjustment
method to estimate the pooled ORs for primary and secondary
endpoints. We compared the pooled ORs of each NOAC to those
of every other NOAC as well as those of aspirin and vitamin K
antagonists. The choice of a ﬁxed or random effect model was
based on the goodness of ﬁt of the model to the data. The
Cochrane x2 (i.e. Q-statistic) was used for model ﬁt in assessing
whether a ﬁxed or random effects model was used for each
endpoint.
As a sensitivity analysis, we added phase II studies to the main
analyses (phase III studies) and recalculated treatment effects to
assess the robustness of the main analyses.
Results
Literature search
Our literature search identiﬁed 139 articles, of which nine were
selected for the primary analyses (Fig. 1). One of these nine articles
was an unpublished RTC of idraparinux [7], which was identiﬁed
while conducting a manual search for clinical trials in TrialResults-
center. Three articles were excluded from the primary analyses
because they were phase II RCTs; however, they were later
included for sensitivity analyses. The agreement for inclusion and
exclusion between investigators was 100%.
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Fig. 1. Flowchart of literature review.
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apixaban [8,9], zero for betrixaban, one for dabigatran [10], one for
edoxaban [11], one for idraparinux [7], two for rivaroxaban [12,13],
and two for ximelagatran [1,2] (Table 1). When multiple doses
were examined in a trial (i.e. dabigatran 110 mg and 150 mg twice
daily in RE-LY; and edoxaban 30 mg and 60 mg once daily in
ENGAGE [11]), they were treated as independent interventions.
The comparator included aspirin and two types of vitamin K
antagonists (warfarin and acenocoumarol). Three studies were of
open label design [1,7,10], and thus the pooled ORs for dabigatran
110 mg, dabigatran 150 mg, ximelagatran, and idraparinux were
subject to adjustment. The three phase II studies (all open label)
included for sensitivity analyses examined apixaban [14] and
dabigatran [15,16].
Deﬁnitions of each component of the primary composite
endpoint varied across studies but were generally similar
(Appendix 2 Table A2). The deﬁnition of major bleeding was also
similar with the exception of the study examining apixaban, which
limited the drop in hemoglobin greater than 2 g/dL within 24 h
[17].
Effect of study design
Pooled ORs for the composite endpoint compared to vitamin K
antagonists ranged from 0.66 (95% CI 0.53–0.82) to 1.81 (95% CI
1.23–2.65) (Fig. 2A). Pooled ORs for major bleeding compared to
vitamin K ranged from 0.62 (95% CI 0.39–0.98) to 2.62 (95% CI
1.70–4.03) (Fig. 2C). When taking study design into account, thepooled ORs for the composite endpoint increased from 0.67 (95% CI
0.37–1.21) to 0.78 (95% CI 0.42–1.44) for idraparinux, from 0.99
(95% CI 0.59–1.65) to 1.07 (95% CI 0.79–1.46) for ximelagatran,
from 0.91 (95% CI 0.74–1.12) to 1.06 (95% CI 0.83–1.36) for
dabigatran 110 mg, and from 0.66 (95% CI 0.37–1.21) to 0.77 (95%
CI 0.59–1.00) for dabigatran 150 mg (Fig. 2B). Pooled ORs from all
double-blind studies were the same.
This trend was also observed in the ORs for major bleeding:
Pooled ORs for major bleeding increased from 2.62 (95% CI 1.70–
4.03) to 3.04 (95% CI 1.93–4.80) for idraparinux, from 0.73 (95% CI
0.55–0.96) to 0.76 (95% CI 0.58–1.01) for ximelagatran, from 0.80
(95% CI 0.69–0.93) to 0.93 (95% CI 0.76–1.15) for dabigatran
110 mg, and from 0.93 (95% CI 0.81–1.08) to 1.08 (95% CI 0.88–
1.33) for dabigatran 150 mg following adjustment (Fig. 2D).
Therefore, we used adjusted pooled ORs for all additional analyses.
Comparisons of NOACs
Aspirin was consistently inferior to all NOACs with respect to
the primary composite endpoint [ORs 1.70 (95% CI 1.08–2.69) to
2.35 (95% CI 1.48–3.75)]. All NOACs were found to perform
similarly (Fig. 3A–F), except for dabigatran 110 mg and edoxaban
30 mg. Particularly, edoxaban 30 mg was signiﬁcantly inferior to
apixaban (OR 1.45, 95% CI 0.55–0.88), rivaroxaban (OR 1.34, 95% CI
0.08–1.44), and dabigatran 150 mg (OR 1.49, 95% CI 1.10–2.02). In
terms of major bleeding, idraparinux was consistently inferior to
all NOACs [ORs 2.81 (95% CI 1.7–4.63) to 6.52 (95% CI 4.03–10.57)]
(Fig. 4A–F). Apixaban and edoxaban 30 mg were signiﬁcantly
Table 1
Summary of included studies.
Study Study design –
double blind
Follow-up
period
Intervention
and dose
Dose
regimen
Patients, n CHADS2
(mean)
No history
of vitamin K
antagonist (%)
Secondary
prevention (%)
Stroke Systemic
embolism
Myocardial
infarction
Major
bleeding
All-cause
mortality
Event, n Event, n Event, n Event, n Event, n
AMADEUS [7] No 0.9 years (mean) Idraparinux 2.5mg (SC) Once a week 2283 24.0 22.6 0 16 74 62
Vitamin K antagonist Once daily 2293 24.1 25.1 2 13 29 61
ARISTOTLE [8] Yes 1.8 years (median) Apixaban 5mg Twice daily 9120 2.1 42.9 19.2 199 15 90 327 603
Vitamin K antagonist Once daily 9081 2.1 42.8 19.7 250 17 102 462 669
AVERROES [9] Yes 1.1 years (mean) Apixaban 5mg Twice daily 2808 2.0 85.7 13.8 49 2 24 44 111
Aspirin (81–324mg) Once daily 2791 2.1 84.7 13.4 105 13 28 39 140
ENGAGE [11] Yes 2.8 years (median) Edoxaban 60mg Once daily 7035 2.8 41.2 28.1 281 15 133 418 773
Edoxaban 30mg Once daily 7034 2.8 40.8 28.5 360 29 169 254 737
Vitamin K antagonist Once daily 7036 2.8 41.2 28.3 317 23 141 524 839
JROCKET [13] Yes 1.3 years (mean) Rivaroxaban 15mg Once daily 640 3.27 9.7 63.8 10 1 1 7
Vitamin K antagonist Once daily 640 3.22 10.3 63.4 21 1 3 5
RELY [10] No 2.0 years (median) Dabigatran 150mg Twice daily 6076 2.2 49.8 20.3 122 89 375 438
Dabigatran 110mg Twice daily 6015 2.1 49.9 19.9 171 86 322 446
Vitamin K antagonist Once daily 6022 2.1 51.4 19.8 185 63 397 487
ROCKET AF [12]* Yes 1.9 years (median) Rivaroxaban 20mg Once daily 7131 3.48 37.7 54.9 184 5 101 395 208
Vitamin K antagonist Once daily 7133 3.46 37.5 54.6 221 22 126 386 250
SPORTIF III [1] No 1.4 years (mean) Ximelagatran 36mg Twice daily 1704 25.6 24.5 4 24 29 78
Vitamin K antagonist Once daily 1703 27.5 23.8 2 13 41 79
SPORTIF V [2] Yes 1.7 years (mean) Ximelagatran 36mg Twice daily 1960 17.5 18.8 6 26 63 116
Vitamin K antagonist Once daily 1962 15.3 17.7 1 37 84 123
Phase II studies for sensitivity analyses
ARISTOTLE-J [14] No 12 weeks Apixaban 5mg Twice daily 74 2.1 12.7 35.1 0 0
Vitamin K antagonist Once daily 74 1.9 16.0 27.0 3 1
PETRO [15] No 12 weeks Dabigatran 150mg Twice daily 166 17.5 0 0
Vitamin K antagonist Once daily 70 18.6 0 0
Phase II
Dabigatran [16]
No 12 weeks Dabigatran 150mg Twice daily 58
Vitamin K antagonist Once daily 62
CHADS2, risk score based on congestive heart failure, hypertension, age75 years, diabetes mellitus, and previous stroke or transient ischemic attack.
SC, subcutaneously.
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Fig. 2. Differences in odds ratios of direct oral anticoagulants between bias corrected and not corrected referenced to warfarin.
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Fig. 3. Odds ratios of composite endpoint of direct oral anticoagulants. A, B, C, D, E, and F are referenced to apixaban, dabigatran 110 mg, dabigatran 150 mg, edoxaban 30 mg,
edoxaban 60 mg, and rivaroxaban, respectively.
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T. Morimoto et al. / Journal of Cardiology 66 (2015) 466–474 471lower in risk of major bleeding compared to dabigatran 110 mg
[OR 0.74 (95% CI 0.58–0.96) and OR 0.50 (95% CI 0.39–0.65),
respectively] (Fig. 4B), dabigatran 150 mg [OR 0.64 (95% CI 0.5–
0.82) and OR 0.43 (95% CI 0.33–0.56)] (Fig. 4C), rivaroxaban [OR
0.68 (95% CI 0.55–0.83) and OR 0.45 (95% CI 0.37–0.56)] (Fig. 4F),
and vitamin K antagonists [OR 0.69 (95% CI 0.60–0.80) and OR 0.47
(95% CI 0.40–0.54)] (Fig. 2D). In addition, edoxaban 30 mg was
signiﬁcantly lower in risk of major bleeding compared to apixaban
(OR 0.67, CI 95% 0.54–0.83) (Fig. 4A), and edoxaban 60 mg (OR 0.59,
CI 95% 0.48–0.73) (Fig. 4E). While the risk of major bleeding was
similar among ximelagatran, dabigatran 110 mg and 150 mg, and
rivaroxaban (Fig. 4B, C, and F), aspirin was superior to vitamin K
antagonists, dabigatran 150 mg, and rivaroxaban (Figs. 2D, 4C and
F).
With respect to secondary endpoints, aspirin was consistently
inferior with ORs ranging from 1.61 (95% CI 1.01–2.58) to 2.31 (95%
CI 1.43–3.72) (Fig. 5A–C, E and F) to all NOACs except edoxaban
30 mg (Fig. 5D) and vitamin K antagonists (data not shown) in
reducing stroke. Vitamin K antagonists were also inferior to
apixaban (Fig. 5A), dabigatran 150 mg (Fig. 5C), and rivaroxaban
(Fig. 5F) in reducing stroke, with pooled ORs of 1.27 (95% CI 1.05–
1.53), 1.33 (95% CI 1.01–1.75), and 1.25 (95% CI 1.03–1.51),
respectively. Edoxaban 30 mg had higher risk of stroke compared
to apixaban, dabigatran 150 mg, edoxaban 60 mg, and rivaroxaban
(Fig. 5D) with pooled ORs of 1.45 (95% CI 1.14–1.85; Fig. 5A), 1.52
(95% CI 1.11–2.08; Fig. 5C), 1.30 (95% CI 1.03–1.62; Fig. 5E), and
1.43 (95% CI 1.12–1.83; Fig. 5F), respectively.0 2 1 
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Fig. 4. Odds ratios of major bleeding of direct oral anticoagulants. A, B, C, D, E, and F are
edoxaban 60 mg, and rivaroxaban, respectively.Vitamin K antagonists, apixaban, edoxaban 60 mg, and
rivaroxaban were superior in reducing myocardial infarction
compared to both dabigatran 110 mg and 150 mg, with ORs
ranging from 0.48 (95% CI 0.31–0.75) to 0.63 (95% CI 0.44–0.90)
(Fig. 5B and C). Rivaroxaban was also signiﬁcantly lower in risk of
myocardial infarction than edoxaban 30 mg (OR 0.66, CI 95% 0.47–
0.93) (Fig. 6D). Otherwise, vitamin K antagonists and all other
NOACs were observed to have a similar effect on myocardial
infarction (Fig. 6A, D–F).
Other endpoints and sensitivity analyses
In terms of all-cause mortality, vitamin K antagonists were
signiﬁcantly inferior to apixaban and edoxaban 30 mg with ORs of
1.12 (CI 95% 1.00–1.26) (Appendix 3 Fig. A3 A) and 1.16 (95% CI
1.04–1.28) (Appendix 3 Fig. A3 D), respectively. All other NOACs as
well as aspirin and, idraparinux were similar in effect on all-cause
mortality (Appendix 3 Fig. A3 A–F). When we considered ischemic
stroke and stroke of unknown origin, aspirin was found to be
inferior to all NOACs and vitamin K antagonists, with the exception
of dabigatran 110 mg and edoxaban 30 mg (Appendix 4 Fig. A4 A–
F). Moreover, apixaban and rivaroxaban were found to be superior
to dabigatran 110 mg in reducing ischemic stroke and stroke of
unknown origin (Appendix 4 Fig. A4 A and C). With respect to
intracranial hemorrhage, idraparinux was consistently inferior to
the NOACs and vitamin K antagonists (Appendix 6 Fig. A6 A–F, data
not shown for vitamin K antagonists).Odds ratios
4 6 853 7
Odds ratios
4 6 853 7
Odds ratios
0 42 6 81 53 7
Odds ratios
0 42 6 81 53 7
gm 011nart Reference : Dabiga tran 15 0 mgC
Aspirin
xunirapardI
nartagalemiX
3.26
0.57
2.81
0.71
0.43
0.95
0.86
0.92
0.64
0.72
Api xaba n
Rivaroxaban
Dabigatran 110  mg
Vitamin K antagonis t
Edoxaban 30  mg
Edoxaban 60  mg
nabaxoraviR :ecnerefeRgm06naba F
Dabigatran 110  mg
Aspirin
Vitamin K antagonis t
Api xaba n
Dabigatran 150  mg
Edoxaban 30  mg
Edoxaban 60  mg
Ximelagatra n
3.87
1.06
0.97
0.60
0.68
0.91
0.45
0.76
0.74
2.96
Idraparinux
 referenced to apixaban, dabigatran 110 mg, dabigatran 150 mg, edoxaban 30 mg,
0 1 2 430 1 2 43
0 1 2 43
Odds ratios
Api xaba n
Rivaroxaban
Dabigatran 110  mg
Vitamin K antagonis t
Aspirin
Dabigatran 150  mg
Edoxaban 60  mg
0.70
0.94
0.69
1.52
0.87
0.77
0.66
0.89
Odds ratios
0 1 2 4
1.22
1.97
1.13
3
0.91
Api xaba n
Rivaroxaban
Dabigatran 110  mg
Vitamin K antagonis t
Aspirin
Dabigatran 150  mg
Edoxaban 30  mg
1.30
0.85
1.10
Odds ratios
0 1 2 43
Api xaba n
Edoxaban 60  mg
Dabigatran 110  mg
Vitamin K antagonis t
Aspirin
Dabigatran 150  mg
Edoxaban 30  mg
1.43
0.98
1.34
2.16
1.25
0.94
Reference : Apix aba n gm 011nartagibaD :ecnerefeRA gm 051nartagibaD :ecnerefeRB C
Odds ratios
Dabigatran 110  mg
Rivaroxaban
Dabigatran 150  mg
Vitamin K antagonis t
Aspirin
Edoxaban 30  mg
Edoxaban 60  mg
1.02
0.95
1.36
2.20
1.27
1.12
1.45
Odds ratios
Api xaba n
Rivaroxaban
Dabigatran 150  mg
Vitamin K antagonis t
Aspirin
Edoxaban 30  mg
Edoxaban 60  mg
0.73
0.70
1.61
0.93
0.75
0.82
1.07
1.07
Odds ratios
1.05
1.43
0 1 2 43
2.31
1.33
Api xaba n
Rivaroxaban
Dabigatran 110  mg
Vitamin K antagonis t
Aspirin
Edoxaban 30  mg
Edoxaban 60  mg
1.17
1.52
Reference:  Edo xab an 30mgD nabaxoraviR :ecnerefeRgm06nabaxodE :ecnerefeR FE
Fig. 5. Odds ratios of stroke of direct oral anticoagulants. A, B, C, D, E, F, and G are referenced to vitamin K antagonist, apixaban, dabigatran 110 mg, dabigatran 150 mg,
edoxaban 30 mg, edoxaban 60 mg, and rivaroxaban, respectively.
T. Morimoto et al. / Journal of Cardiology 66 (2015) 466–474472Pooled ORs and statistical signiﬁcances remained unchanged
following sensitivity analyses with the addition of the three
identiﬁed phase II studies.
Discussion
Our network meta-analysis with adjustment for study design
indicates that the relative efﬁcacies of NOACs in preventing stroke
and systemic embolism in patients with atrial ﬁbrillation are
nearly indistinguishable apart from those of dabigatran and
edoxaban at lower doses. In light of our ﬁndings, it appears likely
that unblinded clinical trials such as the RE-LY study [10]
overestimate the effects of tested drugs. Safety endpoints usually
include ‘‘soft’’ endpoints and, thus, are easily biased by unblinded
study design. Indeed, although dabigatran 110 mg had a lower risk
of bleeding than vitamin K antagonist in unadjusted analysis
(Fig. 2C), this was no longer the case following adjustment for open
label study bias (Fig. 2D).
Blinding is one of the best ways of minimizing biased outcomes
in clinical trials [3,18,19] and is of particular importance in
pharmaceutical-industry funded trials comparing sponsor pro-
ducts with standard treatments [20]. Although blinding the phase
III trials is difﬁcult and costly, the efﬁcacy of newly developed
drugs should be assessed in rigid, reliable study designs to avoid
the introduction of biases. Use of open label study designs is
justiﬁed only in pragmatic trials comparing effectiveness of
treatment strategies using already approved drugs [e.g. Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT)] [21]. AlthoughO’Neal et al. recently reported the lack of a differentiating pattern
of results across phase III NOACs studies between blinded and
unblinded designs [22], their results do not necessarily exclude the
possibility of biased results stemming from open label study
designs.
While similarities were observed among most NOACs in terms
of the primary efﬁcacy endpoint, our network meta-analysis
suggests some key differences between dabigatran and edoxaban
at lower doses and other NOACs in the primary efﬁcacy endpoint
as well as among some NOACs in secondary and safety endpoints.
For example, the RE-LY study [10] demonstrated that treatment
with dabigatran at 150 mg twice daily was associated with an
increased risk of myocardial infarction compared to vitamin K
antagonists, and this was conﬁrmed by a recent meta-analysis
[23] as well as in line with the ﬁndings of our own indirect
comparison wherein treatment with dabigatran (both 110 mg and
150 mg doses) was associated with a higher risk of myocardial
infarction compared to apixaban, rivaroxaban, and edoxaban
60 mg. Although results should be interpreted with caution
because of very few events, a recent clinical trial also suggested a
higher risk for myocardial infarction in dabigatran-treated
patients with venous thromboembolism as compared to warfa-
rin-treated patients [24]. Populations tested in such studies,
however, are not necessarily appropriate for the assessment of
risk of myocardial infarction. Recent two ‘‘new users’’ large cohort
studies showed equivalent or even lower risk of myocardial
infarction in patients with dabigatran compared to those with
warfarin [25,26].
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vitamin K antagonists performed similarly with respect to major
bleeding following adjustment, treatment with apixaban or
edoxaban at either dose was associated with a lower risk of major
bleeding than other NOACs and vitamin K antagonists. However,
inter-study comparison regarding our safety endpoint should be
interpreted with caution, as the deﬁnition of major bleeding varied
among studies (Appendix 2 Table A2).
In terms of statistical heterogeneity, which is often a problem in
meta-analysis, we closely reviewed studies to ensure they were as
comparable as possible to reduce the inﬂuence of heterogeneity.
No dose-ﬁnding studies were included and we restricted our
primary analysis to only Phase III studies and Phase II studies were
restricted to approved doses (same as Phase III studies) and
assessed in a sensitivity analysis only.
Limitation of the study
While useful in making comparisons where such experiments
are infeasible or have yet to be conducted, a number of limitations
exist with regard to the conduct of network analyses. Study
differences, including the heterogeneity of populations, endpoint
deﬁnitions, study designs, and therapeutic doses, all constrain the
strength of network analytic ﬁndings. In our study, we adjusted for
open label study bias but did not adjust for the greater severity of
the ROCKET study population (as evidenced by a higher CHADS2
score) nor the difference in ‘‘major bleeding’’ deﬁnition in the
apixaban studies. To allow for a more ‘‘fair’’ comparison, theadjustment for open label study bias was applied to allow us to
control for the over-estimation of treatment effect in these studies.
However, this strategy carries its own limitations. Although much
work has been done to investigate the inherent treatment effect
bias from open label studies, the results of these efforts are limited
in that validation of these methods remains insufﬁcient despite
their approximation to blinded studies. We selected the method
used by Ju¨ni et al. as it incorporates multiple different studies in a
meta-analysis rather than a single open-blinded comparison, and
should therefore provide a broader representation of the inherent
bias from open-label studies.
Conclusion
Indirect comparison of phase III trials of NOACs suggests that
newly approved NOACs are of near equivalent efﬁcacy following
adjustment by study design apart from dabigatran and edoxaban at
lower doses; however, some differences in safety and risk of
myocardial infarction remain. Furthermore, open label study
designs appear to overestimate efﬁcacy and safety. Differences in
study design should be taken into account in interpretation and
implementation of results from RCTs of NOACs.
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